{"transactions":[{"id":4382,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":50000,"derivative":{"exercise_price":0.032,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4381,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock-option (Right to Buy)","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is reported in U.S. dollars and reflects the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On September 2, 2026, following the implementation of the Remuneration Committee's decision, the exercise price of options was repriced to $0.032. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable."}],"balance_after":0,"derivative":{"exercise_price":0.062,"exercise_date":"2024-01-08","expiration_date":"2034-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4380,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"grant","planned":false,"acquired":true,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":219561,"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":4379,"issuer":{"id":8301,"kind":"organization","name":"Addex Therapeutics Ltd.","symbol":"ADXN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-04T20:06:52.000Z","date":"2026-09-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":219561,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents 219,561 shares of common Stock listed on SIX Swiss Exchange acquired following the exercise of options. Of these shares, 128,238 were acquired on October 26, 2022 under the deferred strike price payment plan with an initial strike price of $0.16 per share and 91,323 were acquired on November 27, 2023 with an initial strike price of $0.053 per share. On September 2, 2026, following the implementation of the Remuneration Committee's decision, the Strike price of all units was reduced to $0.032. All the other terms of the deferred strike price payment plan remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the exchange act as applicable.The strike prices indicated in this section reflect the conversion from CHF to USD at an exchange rate of $1.2296 per CHF 1.00 as of September 2, 2026."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-105501","document":"tm2624769-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1574232/000110465926105501/tm2624769-4_4seq1.xml","form_type":"4"}},{"id":733953,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-17T22:09:56.000Z","date":"2026-06-15","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 15, 2027, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":18500,"derivative":{"exercise_price":18.71,"expiration_date":"2036-06-15","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0001193125-26-274473","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000119312526274473/ownership.xml","form_type":"4"}},{"id":1019200,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-14T21:16:29.000Z","date":"2025-10-09","kind":"purchase","planned":false,"acquired":true,"shares":63158,"price":19,"value":1200002.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Acquired from the Issuer on October 9, 2025 pursuant to a Securities Purchase Agreement dated October 7, 2025."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":1173395,"source":{"system":"sec-edgar","filing":"0001193125-25-239158","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000119312525239158/ownership.xml","form_type":"4"}},{"id":1100135,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":60000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100134,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.01,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100133,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.36,"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100132,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.45,"underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100131,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.7,"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100130,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":9.9,"underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100129,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2325,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to terms of the Merger Agreement, each stock option that was outstanding and unexercised with a per Share exercise price equal to or greater than the Closing Amount but less than $14.00 (each, an \"Out-of-the-Money Option\") was automatically canceled and terminated and converted into the right to receive one CVR with respect to each Share subject to such Out-of-the-Money Option immediately prior to the Effective Time, and therefore may become entitled to receive, as of the date of the Milestone Payment (as defined in the Merger Agreement), an amount in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (i) the aggregate number of CVRs received in respect of such Out-of-the-Money Option by (ii) an amount equal to $14.00, less the per Share exercise price of such Out-of-the-Money Option (provided if no Milestone Payment is made, then no payments will be made with respect to any Out-of-the-Money Option)."}],"balance_after":0,"derivative":{"exercise_price":8.8,"underlying":"Common Stock","underlying_shares":2325},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100128,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4650,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to terms of the Merger Agreement,  each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per Share exercise price less than the Closing Amount (each, an \"In-the-Money Option\") was automatically canceled and terminated and converted into the right to receive (i) a payment in cash (without interest and subject to applicable withholding), if any, equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such In-the-Money Option immediately prior to the Effective Time by (B) an amount equal to the Closing Amount less the per Share exercise price of such In-the-Money Option plus (ii) one CVR with respect to each Share subject to such In-the-Money Option immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.4,"underlying":"Common Stock","underlying_shares":4650},"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1100127,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-27T21:02:30.000Z","date":"2025-06-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":62500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed pursuant to that certain Agreement and Plan of Merger, dated as of April 29, 2025 (the \"Merger Agreement\"), by and among Regulus Therapeutics Inc. (the \"Issuer\"), Redwood Merger Sub Inc. (\"Merger Sub\"), a wholly owned, indirect subsidiary of Novartis AG (\"Parent\"), and Parent. Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 (the \"Shares\"), in exchange for (a) $7.00 in cash per Share (the \"Closing Amount\"), subject to any applicable withholding and without interest thereon, plus (b) one contingent value right (each, a \"CVR\") per Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Each CVR represents the right to receive one contingent payment of $7.00 in cash (the Closing Amount and one CVR, collectively, the \"Offer Price\"), subject to any applicable withholding and without interest thereon, upon the achievement of the milestone specified in, and on the other terms and subject to the other conditions set forth in, that certain CVR Agreement entered into between Parent and a rights agent. Effective as of June 25, 2025, Merger Sub merged with and into the Issuer (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, these Shares were converted into the right to receive the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to terms of the Merger Agreement,  each restricted stock unit that was subject to vesting or forfeiture conditions that was outstanding immediately prior to the Effective Time was automatically canceled and terminated and converted into the right to receive  (i) an amount in cash (without interest and subject to applicable withholding) equal to the product obtained by multiplying (A) the aggregate number of Shares underlying such restricted stock unit immediately prior to the Effective Time by (B) the Closing Amount, plus (ii) one CVR with respect to each Share subject to such restricted stock unit immediately prior to the Effective Time."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-091006","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025091006/ownership.xml","form_type":"4"}},{"id":1113215,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:58:46.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":18500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 100% of the underlying shares of common stock on June 10, 2026, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":18500,"derivative":{"exercise_price":11.94,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":18500},"source":{"system":"sec-edgar","filing":"0000950170-25-085531","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025085531/ownership.xml","form_type":"4"}},{"id":1163330,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T22:16:18.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":62500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 30, 2025, the Reporting Person was granted 62,500 Restricted Stock Units (the \"Award\").  The Award vests in equal monthly installments over the 12 months from the date of grant."}],"balance_after":62500,"source":{"system":"sec-edgar","filing":"0000950170-25-061298","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017025061298/ownership.xml","form_type":"4"}},{"id":1406592,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":5809528,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":669061},"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406591,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":false,"shares":13071439,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Fund II Aggregator, LP, and a limited partner of SR One Capital Partners II, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1505388},"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406590,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-12","kind":"grant","planned":false,"acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests in equal annual installments over three years beginning on September 12, 2025, the first anniversary of the vesting commencement date, subject to continued service."}],"balance_after":37000,"derivative":{"exercise_price":17,"expiration_date":"2034-09-11","underlying":"Common Stock","underlying_shares":37000},"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406589,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":441176,"price":17,"value":7499992.0,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":1110237,"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406588,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":669061,"ownership":{"direct":false,"nature":"See Note 3"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities are held directly by SR One Capital Opportunities Fund I, LP. SR One Capital Opportunities Partners I, LP is the general partner of SR One Capital Opportunities Fund I, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Opportunities Fund I, LP, and a limited partner of SR One Capital Opportunities Partners I, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":669061,"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406587,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"purchase","planned":false,"acquired":true,"shares":441176,"price":17,"value":7499992.0,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Fund II Aggregator, LP, and a limited partner of SR One Capital Partners II, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":1946564,"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1406586,"issuer":{"id":275,"kind":"organization","name":"Zenas BioPharma, Inc.","symbol":"ZBIO"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-17T00:54:53.000Z","date":"2024-09-16","kind":"exercise","planned":false,"acquired":true,"shares":1505388,"ownership":{"direct":false,"nature":"See Note 2"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities are held directly by SR One Capital Fund II Aggregator, LP. SR One Capital Partners II, LP is the general partner of SR One Capital Fund II Aggregator, LP. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Capital Fund II Aggregator, LP, and a limited partner of SR One Capital Partners II, LP. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (\"Section 16\"), except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose."}],"balance_after":1505388,"source":{"system":"sec-edgar","filing":"0000950170-24-106979","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024106979/ownership.xml","form_type":"4"}},{"id":1478873,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T21:40:11.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":0.4,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-24-012665","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000106299324012665/form4.xml","form_type":"4"}},{"id":1507073,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-21T20:23:00.000Z","date":"2024-05-20","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":60000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-19","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-062927","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024062927/ownership.xml","form_type":"4"}},{"id":1511136,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T20:47:48.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of\nStockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the\nCompany's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-05-15","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000950170-24-061778","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000095017024061778/ownership.xml","form_type":"4"}},{"id":1808470,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-14T20:26:13.000Z","date":"2023-08-10","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant, subject to the Reporting Person's continuous service."}],"balance_after":15000,"derivative":{"exercise_price":1.36,"expiration_date":"2033-08-09","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-23-045633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919123045633/doc4.xml","form_type":"4"}},{"id":1849407,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:37:14.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":13700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the options shall vest in full on the first anniversary of the grant date, subject to the reporting person's continuous service through such vesting date."}],"balance_after":13700,"derivative":{"exercise_price":1.04,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":13700},"source":{"system":"sec-edgar","filing":"0001062993-23-013833","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000106299323013833/form4.xml","form_type":"4"}},{"id":1857134,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-13T20:49:04.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":30000,"derivative":{"exercise_price":1.45,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-23-036762","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919123036762/doc4.xml","form_type":"4"}},{"id":2234068,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T21:26:53.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":0.43,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001062993-22-014808","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000106299322014808/form4.xml","form_type":"4"}},{"id":2235791,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-10T20:19:15.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":90000,"derivative":{"exercise_price":0.27,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-22-035874","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919122035874/doc4.xml","form_type":"4"}},{"id":2668163,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-15T20:43:13.000Z","date":"2021-06-14","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":40000,"derivative":{"exercise_price":0.9877,"expiration_date":"2031-06-13","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-040619","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919121040619/doc4.xml","form_type":"4"}},{"id":2686299,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-02T20:58:15.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":68577,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":68577,"derivative":{"exercise_price":1.74,"expiration_date":"2031-05-28","underlying":"Common Stock","underlying_shares":68577},"source":{"system":"sec-edgar","filing":"0001429560-21-000003","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000142956021000003/edgar.xml","form_type":"4"}},{"id":3104213,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:39:41.000Z","date":"2020-06-17","kind":"grant","acquired":true,"shares":23250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Company's Non Employee Director's Compensation policy, the options are automatically granted on the date of the Company's Annual Meeting of Stockholders and will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual stockholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":23250,"derivative":{"exercise_price":0.88,"expiration_date":"2030-06-16","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0001209191-20-037953","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919120037953/doc4.xml","form_type":"4"}},{"id":3147131,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-15T21:26:28.000Z","date":"2020-05-13","kind":"grant","acquired":true,"shares":64103,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting\nperson's continuous service through such vesting date."}],"balance_after":64103,"derivative":{"exercise_price":1.05,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":64103},"source":{"system":"sec-edgar","filing":"0001209191-20-029782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919120029782/doc4.xml","form_type":"4"}},{"id":3252806,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":3000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252805,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252804,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252803,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252802,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.82,"expiration_date":"2026-06-20","underlying":"Common Stock","underlying_shares":10344},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252801,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":10334,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2025-06-10","underlying":"Common Stock","underlying_shares":10334},"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3252800,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-25T02:15:34.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":6000,"price":18.75,"value":112500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001638","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218020001638/primarydocument.xml","form_type":"4"}},{"id":3393609,"issuer":{"id":78034,"kind":"organization","name":"Regulus Therapeutics Inc.","symbol":"RGLS"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-10-15T20:44:22.000Z","date":"2019-10-10","kind":"grant","acquired":true,"shares":46500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest ratably over the following twelve months such that the option will be fully vested one year after the date of grant or on the date of the Company's next annual shareholder meeting, whichever occurs first, subject to the Reporting Person's continuous service."}],"balance_after":46500,"derivative":{"exercise_price":0.64,"expiration_date":"2029-10-09","underlying":"Common Stock","underlying_shares":46500},"source":{"system":"sec-edgar","filing":"0001209191-19-053166","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919119053166/doc4.xml","form_type":"4"}},{"id":3489493,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:16:17.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU, which was granted on June 12, 2018, fully vested on June 12, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003530","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218019003530/primarydocument.xml","form_type":"4"}},{"id":3489492,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T21:16:17.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6000,"source":{"system":"sec-edgar","filing":"0001562180-19-003530","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218019003530/primarydocument.xml","form_type":"4"}},{"id":3498788,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2019-06-07T00:15:38.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001562180-19-003405","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218019003405/primarydocument.xml","form_type":"4"}},{"id":3498787,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2019-06-07T00:15:38.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 4, 2020, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.38,"expiration_date":"2029-06-03","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001562180-19-003405","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000156218019003405/primarydocument.xml","form_type":"4"}},{"id":3523762,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-16T21:37:51.000Z","date":"2019-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.34,"expiration_date":"2029-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-030546","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919119030546/doc4.xml","form_type":"4"}},{"id":3893794,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T22:06:53.000Z","date":"2018-06-13","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"date","element":"transactionDate","label":"F5","text":"The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSU, which was granted on June 13, 2017, fully vested on June 13, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-037836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919118037836/doc4.xml","form_type":"4"}},{"id":3893793,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2018-06-14T22:06:53.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSU will vest 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-18-037836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919118037836/doc4.xml","form_type":"4"}},{"id":3893792,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2018-06-14T22:06:53.000Z","date":"2018-06-12","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will vest and become exercisable as to 100% of the shares on June 12, 2019, subject to the continuing service of the Reporting Person\non such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":9.95,"expiration_date":"2028-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-18-037836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919118037836/doc4.xml","form_type":"4"}},{"id":3893791,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-14T22:06:53.000Z","date":"2018-06-13","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Represents shares acquired upon vesting of Restricted Stock Unit (\"RSU\")  granted on June 13, 2017."}],"balance_after":3000,"source":{"system":"sec-edgar","filing":"0001209191-18-037836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919118037836/doc4.xml","form_type":"4"}},{"id":3927960,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T21:38:49.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.84,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-18-031102","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919118031102/doc4.xml","form_type":"4"}},{"id":4280740,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2017-06-15T21:32:08.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSU will vest 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":3000,"derivative":{"underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001209191-17-040223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919117040223/doc4.xml","form_type":"4"}},{"id":4280739,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2017-06-15T21:32:08.000Z","date":"2017-06-13","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will vest and become exercisable as to 100% of the shares on June 13, 2018, subject to the continuing service of the Reporting Person on such vesting date."}],"balance_after":6000,"derivative":{"exercise_price":28.01,"expiration_date":"2027-06-12","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001209191-17-040223","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919117040223/doc4.xml","form_type":"4"}},{"id":4291018,"issuer":{"id":85383,"kind":"organization","name":"TREVENA INC","symbol":"TRVN"},"owners":[{"id":10038,"kind":"person","name":"Nunn Jason Raleigh","position":1,"cik":"0001444319","reported_name":"Nunn Jason Raleigh","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-06-06T20:50:41.000Z","date":"2017-05-17","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option shall vest in full on the day immediately prior to the next annual stockholders' meeting, subject to the reporting person's continuous service through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":3.08,"expiration_date":"2027-05-17","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-17-038149","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1444319/000120919117038149/doc4.xml","form_type":"4"}}]}